Treatments for Alzheimer’s continue to be lacking in the clinical community. This drug repurposing is hoping to be an effective treatment for mild to moderate AD.
After a delay due to the global pandemic, leading drug delivery company IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) has resumed patient dosing in the ongoing Phase 2a (“BUENA”) clinical trial. Under the previously amended protocol, higher doses of Montelukast VersaFilm are used in patients with mild to moderate Alzheimer’s Disease, per the company’s press release.
IntelGenx management believes that the treatment has the potential to modify treatment of the disease.
Shares were trading up at $0.44 in afternoon trade.